This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Prentice AM (2006) The emerging epidemic of obesity in developing countries. Int J Epidemiol 35: 93–99
King H et al. (1998) Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 21: 1414–1431
Padwal R et al. (2005) A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care 28: 736–744
Staels B and Fruchart JC (2005) Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 54: 2460–2470
Muscat GE and Dressel U (2005) Cardiovascular disease and PPARδ: targeting the risk factors. Curr Opin Investig Drugs 6: 887–894
Acknowledgements
The synopsis was written by Vicky Heath, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Miller, M. Bezafibrate reduces the incidence of type 2 diabetes mellitus in patients with obesity. Nat Rev Endocrinol 2, 198–199 (2006). https://doi.org/10.1038/ncpendmet0157
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpendmet0157